These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 35983982)

  • 1. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.
    Diehl CJ; Ciulli A
    Chem Soc Rev; 2022 Oct; 51(19):8216-8257. PubMed ID: 35983982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    Setia N; Almuqdadi HTA; Abid M
    Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
    Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
    Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
    Ishida T; Ciulli A
    SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs.
    Girardini M; Maniaci C; Hughes SJ; Testa A; Ciulli A
    Bioorg Med Chem; 2019 Jun; 27(12):2466-2479. PubMed ID: 30826187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
    Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
    J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROTAC-mediated crosstalk between E3 ligases.
    Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
    Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the Ubiquitin-Proteasome System (UPS) through PROTAC Technology.
    Cecchini C; Tardy S; Ceserani V; Theurillat JP; Scapozza L
    Chimia (Aarau); 2020 Apr; 74(4):274-277. PubMed ID: 32331546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanding the Structural Diversity at the Phenylene Core of Ligands for the von Hippel-Lindau E3 Ubiquitin Ligase: Development of Highly Potent Hypoxia-Inducible Factor-1α Stabilizers.
    Vu LP; Diehl CJ; Casement R; Bond AG; Steinebach C; Strašek N; Bricelj A; Perdih A; Schnakenburg G; Sosič I; Ciulli A; Gütschow M
    J Med Chem; 2023 Sep; 66(18):12776-12811. PubMed ID: 37708384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Von Hippel-Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein.
    Frost J; Rocha S; Ciulli A
    J Biol Chem; 2021 Aug; 297(2):100910. PubMed ID: 34174286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
    Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
    Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E3 ligase ligand chemistries: from building blocks to protein degraders.
    Sosič I; Bricelj A; Steinebach C
    Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction.
    Buckley DL; Van Molle I; Gareiss PC; Tae HS; Michel J; Noblin DJ; Jorgensen WL; Ciulli A; Crews CM
    J Am Chem Soc; 2012 Mar; 134(10):4465-8. PubMed ID: 22369643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities.
    Galdeano C; Gadd MS; Soares P; Scaffidi S; Van Molle I; Birced I; Hewitt S; Dias DM; Ciulli A
    J Med Chem; 2014 Oct; 57(20):8657-63. PubMed ID: 25166285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and activity study of a novel PI3K degradation by hijacking VHL E3 ubiquitin ligase.
    Wang H; Li C; Liu X; Ma M
    Bioorg Med Chem; 2022 May; 61():116707. PubMed ID: 35344835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298).
    Soares P; Gadd MS; Frost J; Galdeano C; Ellis L; Epemolu O; Rocha S; Read KD; Ciulli A
    J Med Chem; 2018 Jan; 61(2):599-618. PubMed ID: 28853884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7.
    Zoppi V; Hughes SJ; Maniaci C; Testa A; Gmaschitz T; Wieshofer C; Koegl M; Riching KM; Daniels DL; Spallarossa A; Ciulli A
    J Med Chem; 2019 Jan; 62(2):699-726. PubMed ID: 30540463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surface Probing by Fragment-Based Screening and Computational Methods Identifies Ligandable Pockets on the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
    Lucas X; Van Molle I; Ciulli A
    J Med Chem; 2018 Aug; 61(16):7387-7393. PubMed ID: 30040896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ensemble-based virtual screening in discovering potent inhibitors targeting Von Hippel-Lindau (VHL) E3 ubiquitin ligase.
    Liu Y; Lei Y; Guo S; Zuo Z
    Life Sci; 2020 Dec; 262():118495. PubMed ID: 32987061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs.
    Zografou-Barredo NA; Hallatt AJ; Goujon-Ricci J; Cano C
    Bioorg Med Chem; 2023 Jun; 88-89():117334. PubMed ID: 37224698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.